Riociguat denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for riociguat are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Riociguat for Pulmonary Hypertension as Not Medically Necessary

BCBS medical-necessity denials for riociguat — used in pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) — typically arise because the submitted clinical information did not clearly demonstrate that your situation meets BCBS's coverage criteria for this drug. Insurers apply internal medical policies that may require specific diagnostic findings, functional classification documentation, or prior-treatment history to be explicitly documented in the authorization submission. A denial is often a documentation gap, not a clinical disagreement.

## Why This Denial Is Appealable

Medical-necessity denials in serious conditions like pulmonary hypertension are among the most strongly supported categories for appeal. The consequences of under-treatment are well understood, and an insurer's failure to weigh complete clinical evidence in a life-affecting condition is a clear basis for reversal. Under federal law: - ACA §2719 / ERISA §503 guarantee a full-and-fair internal appeal with a written decision that addresses your specific clinical evidence. - External review by an independent clinical reviewer (not BCBS) is available after internal denial; the window is generally up to approximately four months from the denial notice — confirm the exact deadline on your Explanation of Benefits. - Expedited review is available when standard timelines would seriously jeopardize health — which applies in progressive pulmonary hypertension.

## Your Appeal Process and Timeline

1. Request the complete denial file, including the specific BCBS medical policy applied and the exact criteria that were not satisfied. 2. Have your pulmonologist or cardiologist review the denial criteria and prepare a targeted response. 3. File the internal appeal with a complete documentation package — typically within 180 days of the denial notice, but verify on your Explanation of Benefits. 4. If denied, request external review immediately.

## Documentation to Gather

• Diagnostic records: right-heart catheterization results, echocardiogram reports, imaging, and functional capacity assessments (such as six-minute walk test results) from your chart — these are the objective data that establish disease severity.
• Prior-treatment history: names, dates, and documented outcomes for all pulmonary hypertension therapies tried before riociguat.
• Clinical severity documentation: chart notes from your specialist documenting functional class, symptom burden, and disease progression.
• Prescriber medical-necessity letter: a detailed letter from your specialist explaining why riociguat is appropriate for your specific clinical profile, referencing the applicable ACC/AHA or ERS/ESC pulmonary hypertension guideline and the FDA-approved prescribing information.

## Criteria-Mapping Structure

Obtain BCBS's current medical policy for riociguat and the FDA-approved prescribing information. List each coverage criterion in a table, with a column for the exact chart evidence that satisfies it. Attach labeled chart excerpts as exhibits. This format prevents the reviewer from relying on a form denial rather than engaging with the actual clinical record.